Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Diabetes
•
Nephrology
•
Endocrinology
Should GLP1 R agonists be used as first line glucose lowering agents in patients with ESRD and DM?
Related Questions
Are recurrent UTIs a contraindication to SGLT2i use?
How do you adjust your management strategy to address the unique needs of anuric end-stage kidney disease patients when treating diabetic ketoacidosis?
Do you recommend continuous glucose monitoring for patients with Type 2 diabetes who are not on insulin?
Do you use the homeostatic model assessment (HOMA) to assess for insulin resistance and change your clinical management of patients?
How do you distinguish between primary and tertiary hyperparathyroidism in a patient with ESRD?
How long do you wait before reassessing a 24 hour urine calcium level in patients with recurrent nephrolithiasis, hypercalciuria, and osteoporosis who are initiated on bisphosphonate therapy?
What is your experience with the use of automated insulin delivery systems (such as Control IQ with Tandem insulin pumps) in pregnant patients with diabetes?
Would you recommend switching a diabetic CKD patient on oral semaglutide to the subcutaneous form since the benefits in CKD have primarily been reported in studies using subcutaneous GLP-1 receptor agonists?
Has your management of severe hyponatremia changed after a recent observational study described higher in-hospital mortality for sodium correction of <6 mEq/L compared to 6-10 mEq/L in the first 24 hours?
How do you approach a patient with biochemical evidence of primary hyperparathyroidism, but normal parathyroid scan?
